^
Association details:
| Biomarker: | AKT1 mutation + mTOR mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
Published date:
05/19/2021
Excerpt:
Pts with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without mTOR/AKT/PI3Kpathway alterations, received sapanisertib 3mg or 4mg daily together with metformin once to three times daily(500mg - 1500mg)....1/4 pts in PR had AKTand mTORmutation; tumor types included leiomyosarcoma (n = 2), breast (n = 1) and endometrial cancer (n = 1).
DOI:
10.1200/JCO.2021.39.15_suppl.3017
Trial ID:
